Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful
tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring …

Constitutional BRCA1/BRCA2 pathogenic or likely pathogenic variants (PVs) are associated
with an increased risk for developing breast and ovarian cancers. Current evidence …

Our understanding of the molecular mechanisms underlying cancer development and
evolution have evolved rapidly over recent years, and the variation from one patient to …

The personalized medicine is in a rapidly evolving scenario. The identification of actionable
mutations is revolutionizing the therapeutic landscape of tumors. The morphological and …

Simple Summary In the precision oncology era, liquid biopsy has dramatically revolutionized
the management of such patients, potentially overcoming tissue biopsy limitations while …

Cancer is one of the leading causes of death worldwide and remains a major public health
challenge. The introduction of more sensitive and powerful technologies has permitted the …

The diagnostic work-up for non-small cell lung cancer (NSCLC) requires biomarker testing
to guide therapy choices. This article is the second of a two-part series. In Part 1, we …

The development of innovative technologies and the advances in the genetics and
genomics, have offered new opportunities for personalized treatment in oncology. Although …

Abstract Background and Purpose Currently there are no widely accepted guidelines for
chimerism analysis testing in hematopoietic cell transplantation (HCT) patients. The …